Scientists at Columbia University and the Broad Institute have developed evoCAST, a clever gene editing system that addresses a long-standing challenge in gene therapy: how to place entire genes into specific locations in the human genome with precision. Current methods either make small fixes or insert genes randomly, but evoCAST can guide the insertion of complete genes with enough efficiency to make treatments viable.
This advance could change how we approach genetic diseases like cystic fibrosis and haemophilia, where thousands of different mutations can cause the same condition. Instead of creating separate treatments for each mutation variant, evoCAST might allow doctors to use a single therapy that inserts a healthy gene, regardless of which specific mutation a patient has.
The system grew from studying bacterial “jumping genes” that researchers adapted for human cells through a process mimicking evolution. Using the PACE technique to speed up this evolution through hundreds of generations, the team boosted editing efficiency from minimal levels to 30-40% of cells, good enough for many real-world applications.
Beyond treating inherited diseases, evoCAST could improve CAR T-cell therapies for cancer and help researchers who need precise genetic modifications. While getting these tools into the right cells remains challenging, this technology brings us closer to gene therapies that could help patients with previously difficult-to-treat genetic conditions.
Research article: Programmable gene insertion in human cells with a laboratory-evolved CRISPR-associated transposase
Our ODISEI-ONC: Patient-derived cancer organoid-based drug evaluation service
Gastric Cancer Organoid | Breast Cancer Organoid | Hepatocarcinoma Cancer Organoid | Pancreatic Cancer Organoid | >> See more
